Effect of Bifidobacterium Animalis Subsp. Lactis Bi66 Supplementation on Gut Function in Healthy Adults
NCT ID: NCT06740500
Last Updated: 2025-04-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
120 participants
INTERVENTIONAL
2025-10-10
2026-03-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Does Bi66 affect the gut function(bowel movement frequency and stool form)?
2. Does Bi66 affect the gut microbiota and short-chain fatty acids ? Researchers will compare probiotic Bi66 to a placebo (a look-alike substance that contains no Bi66) to see if Bi66 works to affect gut function.
Participants will
1. Take Bi66 or a placebo every day for 8 months
2. Return the used sachets and stool diaries every 7 days and record bowel movement frequency per week and Bristol Stool Scale
3. Have checkups, including questionnaire survey, physical measurement, dietary survey, collection and detection of biological samples at baseline, week 4, week 8
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Investigation of the Effects of a Bifidobacterial Strain on Bowel Movement in Healthy Adults
NCT06686420
Research on the Role of Probiotics in Human Intestinal Health
NCT06886711
Study on the Enhancement of Intestinal and Immune Functions Through Probiotic Intervention
NCT06863415
Effect of Probiotic on the Gut Microbiota of Healthy Volunteers
NCT06103253
Probiotics Improve Health Young Volunteers' Gut Microbiota
NCT06196892
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Probiotic Bi66
Bi66 group adminster a sachet of probiotic powder (1 g), including Bifidobacterium animalis subsp. lactis Bi66 6.0 × 1010 CFU and a maltodextrin carrier once daily for 8 weeks.
Probiotic
probiotic sachet mainly contains Bifidobacterium animalis subsp. lactis Bi66 and maltodextrin.
Placebo
Placebo group adminster a sachet of placebo powder (1 g) containing maltodextrin once daily for 8 weeks.
Placebo
Maltodextrin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Probiotic
probiotic sachet mainly contains Bifidobacterium animalis subsp. lactis Bi66 and maltodextrin.
Placebo
Maltodextrin
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Self-reported bowel movement frequency less than 5 times per week;
* Change of weight no more than 3 kg within the last 2 months;
* No consumption of probiotics, prebiotics, synbiotics within the last 2 months
Exclusion Criteria
* Smoking;
* BMI \< 18 kg/m2 or ≥28 kg/m2;
* Suffering from gastrointestinal disorders such as gastroenteritis, gastroduodenal ulcer, ulcerative colitis, Crohn's disease, intestinal stress syndrome, functional diarrhea, gastroparesis, etc;
* History of gastrointestinal surgery (except appendectomy or hernia repair);
* Change in dietary habits within the last 1 month (e.g. ketogenic diet, etc.);
* History of major surgery within the last 3 months or major surgery planned in the next 1 month;
* Use of antibiotics, acid-suppressing drugs, pro-digestive drugs (gastrointestinal, morpholine, cisapride, etc.), anti-constipation drugs, anti- diarrhea drugs, etc., in the last 1 month;
* Participate in a similar intervention study within the last 1 month
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Huazhong University of Science and Technology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Liegang Liu
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Liegang Liu, PhD
Role: PRINCIPAL_INVESTIGATOR
School of Public Health, Tongji Medical College, Huazhong University of Science and Technology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Huazhong University of Science and Technology
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YY202411
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.